Haematologica (Sep 2024)
A phase I study of MAGE-A1-targeted T1367 T-cell receptor-based cell therapy in patients with advanced multiple myeloma
- Josefine Krüger,
- Matthias Obenaus,
- Igor Wolfgang Blau,
- Dana Hoser,
- Martin Vaegler,
- Hana Rauschenbach,
- Ioannis Anagnostopoulos,
- Korinna Jöhrens,
- Vivian Scheuplein,
- Elisa Kieback,
- Judith Böhme,
- Ann-Christin von Brünneck,
- Jan Krönke,
- Antonia Busse,
- Gerald Willimsky,
- Thomas Blankenstein,
- Antonio Pezzutto,
- Ulrich Keller,
- Axel Nogai
Affiliations
- Josefine Krüger
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin
- Matthias Obenaus
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin
- Igor Wolfgang Blau
- Department of Hematology, Oncology and Cancer Immunology, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 13353 Berlin
- Dana Hoser
- Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin
- Martin Vaegler
- Experimental and Clinical Research Center, Zellkulturlabor für Klinische Prüfung ZKP, Charité-Universitätsmedizin Berlin, Campus Berlin Buch, 13125 Berlin
- Hana Rauschenbach
- Experimental and Clinical Research Center, Zellkulturlabor für Klinische Prüfung ZKP, Charité-Universitätsmedizin Berlin, Campus Berlin Buch, 13125 Berlin
- Ioannis Anagnostopoulos
- Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin
- Korinna Jöhrens
- Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin
- Vivian Scheuplein
- Max-Delbrück-Center for Molecular Medicine, 13125 Berlin
- Elisa Kieback
- Max-Delbrück-Center for Molecular Medicine, 13125 Berlin
- Judith Böhme
- Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin
- Ann-Christin von Brünneck
- Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin
- Jan Krönke
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin; German Cancer Consortium (DKTK), partner site Berlin, a partnership between German Cancer Research Center (DKFZ) and Charité-Universitätsmedizin Berlin, 12203 Berlin
- Antonia Busse
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin; Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, a partnership between German Cancer Research Center (DKFZ) and Charité-Universitätsmedizin Berlin, 12203 Berlin
- Gerald Willimsky
- Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, a partnership between German Cancer Research Center (DKFZ) and Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany; German Cancer Research Center (DKFZ), 69120 Heidelberg
- Thomas Blankenstein
- Max-Delbrück-Center for Molecular Medicine, 13125 Berlin
- Antonio Pezzutto
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin; Max-Delbrück-Center for Molecular Medicine, 13125 Berlin
- Ulrich Keller
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin; Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, a partnership between German Cancer Research Center (DKFZ) and Charité-Universitätsmedizin Berlin, 12203 Berlin
- Axel Nogai
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin
- DOI
- https://doi.org/10.3324/haematol.2024.286124
- Journal volume & issue
-
Vol. 999,
no. 1
Abstract
Not available.
